Predictive Oncology Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Core Insights - Predictive Oncology Inc. has regained compliance with Nasdaq's minimum stockholders' equity requirement of $2,500,000, allowing its shares to continue trading on the Nasdaq Capital Market under the ticker "POAI" [1] - The company is focusing on a digital asset strategy centered around the Aethir network's native utility token, ATH, which aims to create a Strategic Compute Reserve [3] Company Overview - Predictive Oncology utilizes AI and machine learning to enhance early drug discovery, particularly for cancer treatment, with its AI platform, PEDAL, achieving a 92% accuracy rate in predicting tumor responses to drug compounds [2] - The company maintains a biobank of over 150,000 assay-capable heterogeneous human tumor samples, providing extensive resources for drug discovery [2] Digital Asset Strategy - The digital asset treasury strategy involves holding ATH tokens, positioning the company as an operator within the Aethir ecosystem, which aims to democratize access to AI infrastructure globally [3]